| Vol. 10.34 – 30 August, 2022 |
| |
|
|
| Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumours. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers assessed whether tumor immune contexture influenced clinical outcomes after axicabtagene ciloleucel. They evaluated the tumor microenvironment of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 Phase II trial. [Nature Medicine] |
|
|
|
| To complement GWASs and better define actionable biological targets, scientists analyzed sequence data from more than 30,000 patients with Crohn’s disease and 80,000 population controls. [Nature Genetics] |
|
|
|
| The authors analyzed the effects of decitabine on myeloid-derived suppressor cells (MDSCs) from patients with immune thrombocytopenia, both in vitro and in vivo, and found that low-dose decitabine promoted the generation of MDSCs, and enhanced their aerobic metabolism and immunosuppressive functions. [Blood] |
|
|
|
| Investigators examined the heterogeneity of CD8+ T cells in tumors, metastatic lymph nodes, and peripheral blood from patients with early breast cancer. [Science Immunology] |
|
|
|
| Scientists identified Ly6C+/CD11b+ inflammatory monocytes as the primary source of IFNβ and found that active type-I-IFN signaling in tumor-infiltrating inflammatory monocytes was associated with T cell expansion in patients treated with immune checkpoint blockade. [Nature Communications] |
|
|
|
| The authors generated an atlas of 166,533 cells from ten gastric cancer patients with matched paratumor tissues and blood. Their results showed tumor-associated stromal cells had upregulated activity of Wnt signaling and angiogenesis, and were negatively correlated with survival. [Nature Communications] |
|
|
|
| Researchers demonstrated that PD-1+CD8+ T cells functioned as an independent adverse prognosticator in gastric cancer (GC). In addition, an abundance of intratumoral PD-1+CD8+ T cells indicated worse chemotherapeutic responsiveness to fluorouracil in Stage III GC patients. [British Journal of Cancer] |
|
|
|
| Scientists evaluated long-term survival and late effects in 137 patients affected by thalassemia major who received an allogeneic hematopoietic cell transplantation. [Bone Marrow Transplantation] |
|
|
|
| Investigators showed that the sequential use of different T cell redirection therapies was possible and could lead to deep and durable responses following relapse after bispecific antibody therapy in relapsed/refractory multiple myeloma. [Blood Advances] |
|
|
|
| Researchers constructed and screened binders in an single chain Fv format library to generate a new anti-B7-H3 CAR-T with favorable properties. This allowed access to numerous specificities ready formated for CAR evaluation. [Molecular Therapy-Oncolytics] |
|
|
|
| The authors investigated the mechanistic role of cytokine-induced SH2 protein (CISH) in regulating human T cell effector function in solid tumors and demonstrated that CRISPR/Cas9 disruption of CISH enhanced tumor-infiltrating lymphocyte neoantigen recognition and response to checkpoint blockade. [Med] |
|
|
|
| All patients enrolled in the VITAL trial of maintenance gemogenovatucel-T vs. placebo as front-line therapy with homologous recombination proficient stage IIIB-IV newly diagnosed ovarian cancer underwent NanoString gene expression analysis. [Communications Medicine] |
|
|
|
|
| In light of the immune checkpoint inhibition revolution in cancer therapy, scientists review eosinophil–lymphocyte interactions in the tumor microenvironment. [Nature Immunology] |
|
|
|
| Investigators summarize the progress of immunotherapy for the treatment of hepatocellular carcinoma including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies. [Clinical and Experimental Medicine] |
|
|
|
|
| Regen BioPharma, Inc. announced the development of a novel immunotherapy for treatment of solid tumors. The current approach developed by the company involves initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells. [Regen BioPharma, Inc. (Cision US, Inc.)] |
|
|
|
| Century Therapeutics, Inc. announced that the company has been notified by the US FDA that the company’s ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B cell malignancies. [Century Therapeutics, Inc.] |
|
|
|
|
| November 10 – 12, 2022 Bordeaux, France |
|
|
|
|
|
| STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Olivia Newton-John Cancer Research Institute – Victoria, Australia |
|
|
|
| Melanoma Institute Australia – Sydney, Australia |
|
|
|
| Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
|
|